PARIS--(BUSINESS WIRE)--Arterial Remodeling Technologies (“ART”) announced today that it will disclose new data related to its bioresorbable stent platform—additional data that further validates the Company’s innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent. The data will be disclosed by CEO Machiel van der Leest on Thursday, May 6, 2010, at the 9th annual ‘EBR (Endocardiac Biomechanics Research) Symposium 2010’ in Marseille, France.
